Cancer is one of the most dangerous and deadly diseases of all-time. This illness can manifest itself in the organs of the human body and spread throughout the body if left untreated. If the cancer isn’t treated or removed in a timely fashion, death is the general outcome. There are numerous high-level, cancer-research companies around the world, but the United States is home to one of the very best. This company is known as Seattle Genetics, and it is setting new benchmarks in cancer research. President and CEO Clay Siegall is the man of the hour, and he has been “the man” for quite some time.
When speaking on highly accomplished individuals, this guy stands at the forefront of the industry. Dr. Siegall has multiple medical degrees, has at least 15 patents under his belt and has brought about a new change in cancer research. In addition to that, this spectacular man has written over 70 medical-related publications. Yes, this is correct. Dr. Siegall started Seattle Genetics back in the late 1990s, but it wasn’t always a huge success. In its early stages, the company struggled mightily, and it didn’t really start to earn huge amounts of capital until 10 years after securing its IPO. It turned-out that Seattle Genetics was spending more than it was earning, which will pretty much give any business a huge setback. Dr. Siegall had to sit down and come-up with a new strategy. By implementing a sales staff, the company was able to dig itself from a huge hole. This staff would begin to secure multiple seven-figure deals.
Progressive thinking like this is why Seattle Genetics is at the pinnacle of the industry. It has one of the most popular cancer-fighting drugs of all-time, and it has many more advanced drugs in its pipeline. The future is looking mighty bright for cancer research as well as for cancer sufferers.